| scholarly article | Q13442814 |
| P2093 | author name string | Jonas Eriksson | |
| Stina Syvänen | |||
| P2860 | cites work | Synthesis and preclinical evaluation of [11C]D617, a metabolite of (R)-[11C]verapamil | Q48723948 |
| Toward an improved prediction of human in vivo brain penetration | Q48852162 | ||
| The influence of mass of [11C]-laniquidar and [11C]-N-desmethyl-loperamide on P-glycoprotein blockage at the blood-brain barrier | Q48872323 | ||
| Enhanced cerebral uptake of receptor ligands by modulation of P-glycoprotein function in the blood-brain barrier | Q50108149 | ||
| Blood-brain barrier P-glycoprotein function in Alzheimer's disease. | Q50778486 | ||
| Developmental changes in P-glycoprotein function in the blood-brain barrier of nonhuman primates: PET study with R-11C-verapamil and 11C-oseltamivir. | Q51867355 | ||
| Imaging multidrug resistance P-glycoprotein transport function using microPET with technetium-94m-sestamibi. | Q53580923 | ||
| Influence of P-glycoprotein on brain uptake of [18F]MPPF in rats | Q73163374 | ||
| In vivo delineation of 5-HT1A receptors in human brain with [18F]MPPF | Q73192746 | ||
| Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates | Q73764953 | ||
| Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding | Q24657908 | ||
| Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data | Q28274520 | ||
| (R)-[11C]verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus | Q30993837 | ||
| beta-Amyloid efflux mediated by p-glycoprotein | Q31962046 | ||
| PET radiotracers: crossing the blood-brain barrier and surviving metabolism | Q33585028 | ||
| P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide | Q33797745 | ||
| Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites | Q33832954 | ||
| Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease | Q33862071 | ||
| Discrepancies in the P-glycoprotein-mediated transport of (18)F-MPPF: a pharmacokinetic study in mice and non-human primates. | Q48490305 | ||
| Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats | Q48496774 | ||
| Kinetics and displacement of [11C]RO 15-1788, a benzodiazepine antagonist, studied in human brain in vivo by positron tomography. | Q48496931 | ||
| Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography | Q48502840 | ||
| Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET. | Q48507860 | ||
| Pharmacokinetic consequences of active drug efflux at the blood-brain barrier | Q48598406 | ||
| Estimates of Michaelis-Menten constants for the two membranes of the brain endothelium | Q48660778 | ||
| A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier | Q33863406 | ||
| N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier | Q33891067 | ||
| New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kinetics | Q33987752 | ||
| Drug resistance in brain diseases and the role of drug efflux transporters. | Q33988704 | ||
| 11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux | Q34010493 | ||
| Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport | Q34014920 | ||
| Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability | Q34057451 | ||
| Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography | Q34067336 | ||
| Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data | Q34100185 | ||
| Serotonin 5HT2 receptor imaging in the human brain using positron emission tomography and a new radioligand, [18F]altanserin: results in young normal controls | Q34305236 | ||
| Positron emission tomography compartmental models | Q34327907 | ||
| Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers | Q34343207 | ||
| Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects | Q34356874 | ||
| Brain distribution of cetirizine enantiomers: comparison of three different tissue-to-plasma partition coefficients: K(p), K(p,u), and K(p,uu). | Q34469599 | ||
| Review of immunological and immunopathological findings in schizophrenia | Q34487620 | ||
| P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells | Q34538994 | ||
| Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET | Q34572780 | ||
| Consensus nomenclature for in vivo imaging of reversibly binding radioligands | Q34630958 | ||
| The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). | Q36015358 | ||
| Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms | Q36157234 | ||
| P-glycoprotein function at the blood-brain barrier: effects of age and gender | Q36382013 | ||
| Pharmacokinetic modeling of P-glycoprotein function at the rat and human blood-brain barriers studied with (R)-[11C]verapamil positron emission tomography | Q36462753 | ||
| Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. | Q36772901 | ||
| A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer | Q36935382 | ||
| Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET. | Q36947632 | ||
| A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET | Q36949068 | ||
| Synthesis and preclinical evaluation of the radiolabeled P-glycoprotein inhibitor [(11)C]MC113. | Q36949082 | ||
| Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor | Q36949086 | ||
| Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier | Q36949089 | ||
| Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. | Q36949815 | ||
| Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. | Q36949854 | ||
| PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo | Q36953090 | ||
| A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier | Q36955931 | ||
| On the rate and extent of drug delivery to the brain. | Q37023904 | ||
| Immuno-PET: a navigator in monoclonal antibody development and applications. | Q37047713 | ||
| Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges | Q37076348 | ||
| Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function | Q37105870 | ||
| P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys | Q37120685 | ||
| The antiepileptic drug mephobarbital is not transported by P-glycoprotein or multidrug resistance protein 1 at the blood-brain barrier: a positron emission tomography study | Q37185659 | ||
| Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography. | Q37318975 | ||
| Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications | Q37353400 | ||
| Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans | Q37369295 | ||
| Human brain imaging and radiation dosimetry of 11C-N-desmethyl-loperamide, a PET radiotracer to measure the function of P-glycoprotein | Q37474224 | ||
| Using PET studies of P-gp function to elucidate mechanisms underlying the disposition of drugs. | Q37774380 | ||
| Carbon-11 labeled tracers for in vivo imaging P-glycoprotein function: kinetics, advantages and disadvantages. | Q37774382 | ||
| Three decades of P-gp inhibitors: skimming through several generations and scaffolds. | Q37976863 | ||
| Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography | Q39515213 | ||
| Validation of tomographic measurement of cerebral blood volume with C-11-labeled carboxyhemoglobin | Q39712316 | ||
| Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. | Q39855572 | ||
| LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. | Q40528558 | ||
| (R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. | Q40633547 | ||
| Evaluation of 11C-colchicine for PET imaging of multiple drug resistance. | Q40774166 | ||
| Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein | Q40885386 | ||
| Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET. | Q41172348 | ||
| Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier. | Q41823653 | ||
| P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model | Q41844698 | ||
| [11C]Flumazenil brain uptake is influenced by the blood-brain barrier efflux transporter P-glycoprotein | Q42153842 | ||
| [11C]phenytoin revisited: synthesis by [11C]CO carbonylation and first evaluation as a P-gp tracer in rats | Q42354388 | ||
| Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: a PET study with [(11)C]verapamil as a probe for P-glycoprotein function | Q42974372 | ||
| Synthesis and evaluation of [11C]XR9576 to assess the function of drug efflux transporters using PET. | Q43111234 | ||
| Comment regarding Bergmann et al.'s "Assessment of the in vitro and in vivo properties of a 99mTc-labeled inhibitor of the multidrug resistant gene product of P-glycoprotein". | Q44454372 | ||
| Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET. | Q44671680 | ||
| Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier | Q44748118 | ||
| Synthesis and preclinical evaluation of novel PET probes for P-glycoprotein function and expression. | Q45967469 | ||
| In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [(11)C]gefitinib | Q46073165 | ||
| Noninvasive and quantitative assessment of the function of multidrug resistance-associated protein 1 in the living brain | Q46264183 | ||
| Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography | Q46551897 | ||
| Synthesis and evaluation of dopamine D3 receptor antagonist 11C-GR218231 as PET tracer for P-glycoprotein | Q46639262 | ||
| Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier | Q46668112 | ||
| Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration | Q46688887 | ||
| Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease. | Q46714452 | ||
| A method for the synthesis of an oseltamivir PET tracer. | Q46869398 | ||
| Imaging of P-glycoprotein-mediated pharmacoresistance in the hippocampus: proof-of-concept in a chronic rat model of temporal lobe epilepsy. | Q48127121 | ||
| Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil | Q48176609 | ||
| Altered GABAA receptor density and unaltered blood-brain barrier transport in a kainate model of epilepsy: an in vivo study using 11C-flumazenil and PET. | Q48300046 | ||
| Effect of a P-glycoprotein inhibitor, Cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [11C](R)-(-)-RWAY. | Q48363502 | ||
| Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography | Q48370689 | ||
| Quantification of serotonin 5-HT1A receptors in monkey brain with [11C](R)-(-)-RWAY. | Q48429445 | ||
| Symptom provocation in specific phobia affects the substance P neurokinin-1 receptor system | Q48430375 | ||
| Cerebral blood flow, blood volume, and brain tissue hematocrit during isovolemic hemodilution with hetastarch in rats | Q48463932 | ||
| Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET. | Q48466700 | ||
| Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans | Q48476417 | ||
| P433 | issue | 2 | |
| P921 | main subject | blood–brain barrier | Q221694 |
| P304 | page(s) | 225-237 | |
| P577 | publication date | 2012-12-04 | |
| P1433 | published in | ACS Chemical Neuroscience | Q2819059 |
| P1476 | title | Advances in PET imaging of P-glycoprotein function at the blood-brain barrier | |
| P478 | volume | 4 |
| Q92257741 | ABC Transporters at the Blood-Brain Interfaces, Their Study Models, and Drug Delivery Implications in Gliomas |
| Q39029387 | ABCB1 genotyping in the treatment of depression |
| Q92649497 | Age-Related Functional and Expressional Changes in Efflux Pathways at the Blood-Brain Barrier |
| Q38646588 | Blood-Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies. |
| Q42484273 | Blood-brain and retinal barriers show dissimilar ABC transporter impacts and concealed effect of P-glycoprotein on a novel verapamil influx carrier |
| Q47910464 | Blood-brain barrier dysfunction and recovery after ischemic stroke |
| Q38420352 | Clinical Applications of Simultaneous PET/MR Imaging Using (R)-[11C]-Verapamil with Cyclosporin A: Preliminary Results on a Surrogate Marker of Drug-Resistant Epilepsy. |
| Q38369228 | Compounds for imaging amyloid-β deposits in an Alzheimer's brain: a patent review |
| Q26749755 | Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT |
| Q33875271 | Drug-Resistant Epilepsy: Multiple Hypotheses, Few Answers |
| Q89225010 | Dual targeting agents for Aβ plaque/P-glycoprotein and Aβ plaque/nicotinic acetylcholine α4β2* receptors-potential approaches to facilitate Aβ plaque removal in Alzheimer's disease brain |
| Q39290800 | Efflux proteins at the blood-brain barrier: review and bioinformatics analysis |
| Q88656413 | Epigenetic Alterations Impact on Antipsychotic Treatment in Elderly Patients |
| Q38670162 | Fluorine-18 patents (2009-2015). Part 1: novel radiotracers |
| Q26781578 | Herpes Simplex Virus Type 1 and Other Pathogens are Key Causative Factors in Sporadic Alzheimer's Disease |
| Q58786722 | IL-1β, IL-6, TNF- α and CRP in Elderly Patients with Depression or Alzheimer's disease: Systematic Review and Meta-Analysis |
| Q37124197 | Induction of P-glycoprotein by antiretroviral drugs in human brain microvessel endothelial cells |
| Q38117056 | Methodologies to assess drug permeation through the blood-brain barrier for pharmaceutical research |
| Q27004226 | Neuroinflammation in Alzheimer's disease |
| Q90286792 | Noninvasive 11C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis |
| Q38351240 | Radiopharmaceuticals for assessing ABC transporters at the blood-brain barrier. |
| Q47118949 | Synthesis and Evaluation of [(18)F]RAGER: A First Generation Small-Molecule PET Radioligand Targeting the Receptor for Advanced Glycation Endproducts. |
| Q52964010 | Synthesis and In Vivo Imaging of N-(3-[11C]Methoxybenzyl)-2-(3-Methoxyphenyl)ethylaniline as a Potential Targeting Agent for P-glycoprotein. |
| Q57191515 | Synthesis and preliminary preclinical evaluation of fluorine-18 labelled isatin-4-(4-methoxyphenyl)-3-thiosemicarbazone ([F]4FIMPTC) as a novel PET tracer of P-glycoprotein expression |
| Q39018707 | WONOEP appraisal: Imaging biomarkers in epilepsy |
Search more.